Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 5
2004 5
2005 5
2006 7
2007 2
2008 1
2009 5
2010 5
2011 4
2012 2
2013 4
2014 5
2015 3
2016 2
2017 1
2018 1
2019 7
2020 4
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

68 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean de jonge mj (114 results)?
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE. van der Velden DL, et al. Among authors: de jonge mja. Nature. 2019 Oct;574(7776):127-131. doi: 10.1038/s41586-019-1600-x. Epub 2019 Sep 30. Nature. 2019. PMID: 31570881 Clinical Trial.
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH. Hurley RM, et al. Among authors: de jonge mja. Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25. Gynecol Oncol. 2019. PMID: 30686551 Free PMC article. Clinical Trial.
Aurora kinase inhibitors.
Kitzen JJ, de Jonge MJ, Verweij J. Kitzen JJ, et al. Crit Rev Oncol Hematol. 2010 Feb;73(2):99-110. doi: 10.1016/j.critrevonc.2009.03.009. Epub 2009 Apr 14. Crit Rev Oncol Hematol. 2010. PMID: 19369091 Review.
Renal toxicities of chemotherapy.
de Jonge MJ, Verweij J. de Jonge MJ, et al. Semin Oncol. 2006 Feb;33(1):68-73. doi: 10.1053/j.seminoncol.2005.11.011. Semin Oncol. 2006. PMID: 16473645 Review.
Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).
van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, de Bono JS, Schellens JHM. van der Noll R, et al. Among authors: de jonge mja. Invest New Drugs. 2020 Aug;38(4):1117-1128. doi: 10.1007/s10637-019-00856-7. Epub 2019 Oct 30. Invest New Drugs. 2020. PMID: 31667659
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, de Bono JS, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, De Grève J, Schellens JHM. van der Noll R, et al. Among authors: de jonge mja. Invest New Drugs. 2020 Aug;38(4):1096-1107. doi: 10.1007/s10637-019-00857-6. Epub 2019 Oct 21. Invest New Drugs. 2020. PMID: 31637669
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.
van Bussel MTJ, Awada A, de Jonge MJA, Mau-Sørensen M, Nielsen D, Schöffski P, Verheul HMW, Sarholz B, Berghoff K, El Bawab S, Kuipers M, Damstrup L, Diaz-Padilla I, Schellens JHM. van Bussel MTJ, et al. Among authors: de jonge mja. Br J Cancer. 2020 Nov 24. doi: 10.1038/s41416-020-01151-6. Online ahead of print. Br J Cancer. 2020. PMID: 33230210
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.
de Jonge MJA, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DAJ, Abdul Razak AR, De Vos FYFL, Verheijen RB, Schnell D, Pronk LC, Jansen M, Siu LL. de Jonge MJA, et al. Target Oncol. 2019 Feb;14(1):43-55. doi: 10.1007/s11523-018-00617-1. Target Oncol. 2019. PMID: 30756308 Free PMC article. Clinical Trial.
Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
Posadas EM, Chi KN, de Wit R, de Jonge MJA, Attard G, Friedlander TW, Yu MK, Hellemans P, Chien C, Abrams C, Jiao JJ, Saad F. Posadas EM, et al. Among authors: de jonge mja. Clin Cancer Res. 2020 Jul 15;26(14):3517-3524. doi: 10.1158/1078-0432.CCR-19-3402. Epub 2020 May 4. Clin Cancer Res. 2020. PMID: 32366670
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.
Verheijen RB, van der Biessen DAJ, Hotte SJ, Siu LL, Spreafico A, de Jonge MJA, Pronk LC, De Vos FYFL, Schnell D, Hirte HW, Steeghs N, Lolkema MP. Verheijen RB, et al. Among authors: de jonge mja. Target Oncol. 2019 Feb;14(1):67-74. doi: 10.1007/s11523-018-00618-0. Target Oncol. 2019. PMID: 30742245 Free PMC article. Clinical Trial.
68 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback